Boothbay Fund Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Boothbay Fund Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$648K	Buy	+36,060	New	+$558K	0.01%	1347
2025 Q1	–	Sell	-80,543	Closed	-$304K	–	1384
2024 Q4	$304K	Sell	80,543 -4,934	-6%	-$23.2K	0.01%	1063
2024 Q3	$277K	Hold	85,477	–	–	0.01%	1284
2024 Q2	$162K	Sell	85,477 -17,300	-17%	-$33.5K	﹤0.01%	1316
2024 Q1	$292K	Sell	102,777 -116,564	-53%	-$1.52M	0.01%	1198
2023 Q4	$3.23M	Buy	+219,341	New	+$3.36M	0.08%	336
2022 Q3	–	Sell	-34,500	Closed	-$861K	–	2218
2022 Q2	$664K	Sell	34,500 -13,771	-29%	-$163K	0.02%	1024
2022 Q1	$620K	Buy	+48,271	New	+$1.09M	0.01%	1178

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Boothbay Fund Management's AMLX Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 36,060 shares worth $648K. The stake represents 0.01% of the portfolio and ranks #1347 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in AMLX as recently as Q4 2024.

Boothbay Fund Management first reported a position in AMLX in Q1 2022 and has held it in 8 quarters since. The position peaked at $3.23M in Q4 2023. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Boothbay Fund Management held 36,060 shares of Amylyx Pharmaceuticals worth $648K as of Q2 2026.
Amylyx Pharmaceuticals was a new Boothbay Fund Management position in Q2 2026.
Amylyx Pharmaceuticals made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1347 holding.
Boothbay Fund Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 8 quarters since.
Boothbay Fund Management's Amylyx Pharmaceuticals position peaked at $3.23M in Q4 2023.
206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.